CRC for cell therapy manufacturing - driving the CT industry in Australia

There's a long history in cancer medicine of use of histological techniques to identify markers in tumour tissue which provided indication of prognosis. So it's perhaps not surprising that the field of oncology has seen the most rapid engagement with personalised medicine, in particular the advent of oncology medicines which require patient stratification using genotyping diagnostics. As understanding of cancer genetics has advanced, the past decade has seen a range of oncology medicines marketed alongside a companion diagnostic (CDx), which identifies a particular genotype that in turn determines likely therapeutic response to the medicine.